Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study.
Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study.
复制标题
DOI:
10.1007/s11136-021-02943-w
复制
发表时间:
2022-04
期刊:
影响因子:
--
通讯作者:
Flynn KE
中科院分区:
文献类型:
--
作者:
D'Souza A;Myers J;Cusatis R;Dispenzieri A;Finkel M;Panepinto J;Flynn KE
Light chain (AL) amyloidosis is a plasma cell neoplasm associated with high early mortality and severe morbidity that can cause severe disability. We explored the impact of AL amyloidosis on symptoms and well-being from the perspectives of patients and health care providers who regularly care for AL patients. We intended to develop a conceptual understanding of patient-reported outcomes in AL amyloidosis to identify the context of use and concept of interest for a clinical outcome assessments tool in this disease. Twenty patients and ten professionals were interviewed. Patient interviews captured the spectrum of amyloidosis experience including time from diagnosis, type of organ involvement, and presence and type of treatment received. Interviews with professionals included physicians, advanced practice providers, registered nurse, and a patient advocate; these interviews covered similar topics. The impact of AL amyloidosis on patients’ life was multidimensional, with highly subjective perceptions of normality and meaning. Four major themes from patients and experts included diagnosis of AL amyloidosis, living with AL amyloidosis, symptom burden, and social roles. Barriers to patient-reported outcomes data collection in patients were additionally explored from experts. The themes provide a comprehensive understanding of the important experiences of symptom burden and its impact on daily life from AL amyloidosis patients’ and from the perspectives of professionals who care for patients with AL amyloidosis. These findings further the conceptual understanding and identification of a preliminary model of concept of interest for development of a clinical outcome assessments tool for AL amyloidosis.
登录
查看更多内容
影响因子:
3.2
作者:
Hsieh, HF;Shannon, SE
通讯作者:
Shannon, SE
影响因子:
4.3
作者:
Hays, Ron D.;Spritzer, Karen L.;Amtmann, Dagmar;Lai, Jin-Shei;DeWitt, Esi Morgan;Rothrock, Nan;DeWalt, Darren A.;Riley, William T.;Fries, James F.;Krishnan, Eswar
通讯作者:
Krishnan, Eswar
影响因子:
20.3
作者:
Muchtar, Eli;Gertz, Morie A.;Dispenzieri, Angela
通讯作者:
Dispenzieri, Angela
影响因子:
6.5
作者:
Sanchorawala V;McCausland KL;White MK;Bayliss MS;Guthrie SD;Lo S;Skinner M
通讯作者:
Skinner M
影响因子:
3.8
作者:
Lousada, Isabelle;Comenzo, Raymond L.;Merlini, Giampaolo
通讯作者:
Merlini, Giampaolo